These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 19323659)
61. Activated mTORC1 signaling: The common driving force of type 2 diabetes and hidradenitis suppurativa. De Vita V; Melnik BC J Am Acad Dermatol; 2018 May; 78(5):e121. PubMed ID: 29678383 [No Abstract] [Full Text] [Related]
62. Evaluation of barriers to therapeutic drug monitoring in the management of hidradenitis suppurativa. Hilerowicz Y; Levin NJ; Parmar J; Halavi A; Lev-Tov H Clin Exp Dermatol; 2021 Jul; 46(5):936-938. PubMed ID: 33576504 [No Abstract] [Full Text] [Related]
63. Study answers long-standing question about metformin after heart attack. Caffrey MK Am J Manag Care; 2014 May; 20(8 Spec No.):E14. PubMed ID: 25617933 [No Abstract] [Full Text] [Related]
64. Hidradenitis suppurativa and diabetes: big data bias masks a true association. Frew JW Clin Exp Dermatol; 2019 Jun; 44(4):e151-e152. PubMed ID: 30802992 [No Abstract] [Full Text] [Related]
65. Metformin for the treatment of hidradenitis suppurativa: a little help along the way. Verdolini R; Clayton N; Smith A; Alwash N; Mannello B J Eur Acad Dermatol Venereol; 2013 Sep; 27(9):1101-8. PubMed ID: 22882365 [TBL] [Abstract][Full Text] [Related]
66. Metformin use in hidradenitis suppurativa. Jennings L; Hambly R; Hughes R; Moriarty B; Kirby B J Dermatolog Treat; 2020 May; 31(3):261-263. PubMed ID: 30893570 [No Abstract] [Full Text] [Related]
67. Hidradenitis suppurativa: A practical review of possible medical treatments based on over 350 hidradenitis patients. Scheinfeld N Dermatol Online J; 2013 Apr; 19(4):1. PubMed ID: 24021361 [TBL] [Abstract][Full Text] [Related]
68. Metformin in Hidradenitis Suppurativa: Is It Worth Pursuing Further? Tsentemeidou A; Vakirlis E; Papadimitriou I; Ioannides D; Sotiriou E Skin Appendage Disord; 2023 Jun; 9(3):187-190. PubMed ID: 37325287 [TBL] [Abstract][Full Text] [Related]
69. Overexpression of hypoxia-inducible factor-1α in hidradenitis suppurativa: the link between deviated immunity and metabolism. Agamia NF; Sorror OA; Sayed NM; Ghazala RA; Echy SM; Moussa DH; Melnik BC Arch Dermatol Res; 2023 Sep; 315(7):2107-2118. PubMed ID: 36961533 [TBL] [Abstract][Full Text] [Related]
70. The Skin and Gut Microbiome in Hidradenitis Suppurativa: Current Understanding and Future Considerations for Research and Treatment. Luck ME; Tao J; Lake EP Am J Clin Dermatol; 2022 Nov; 23(6):841-852. PubMed ID: 36116091 [TBL] [Abstract][Full Text] [Related]
72. A Molecular Perspective on the Potential Benefits of Metformin for the Treatment of Inflammatory Skin Disorders. Chang JE; Choi MS Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255783 [TBL] [Abstract][Full Text] [Related]
74. Metformin - For the dermatologist. Bubna AK Indian J Pharmacol; 2016; 48(1):4-10. PubMed ID: 26997714 [TBL] [Abstract][Full Text] [Related]
75. An Update on Medical Treatment Options for Hidradenitis Suppurativa. Deckers IE; Prens EP Drugs; 2016 Feb; 76(2):215-29. PubMed ID: 26659474 [TBL] [Abstract][Full Text] [Related]